A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs DNL-747 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 06 Nov 2019 According to a Denali Therapeutics media release, enrollment of an ALS open label extension in the Netherlands has commenced.
- 05 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 05 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.